Halozyme Therapeutics Cash Flow Statement (2010-2026) | HALO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.09M	165.14M	175.26M	-141.59M	150.05M
Share-based Compensation (Quarter)	5.37M	5.40M	5.13M	4.74M	5.63M	6.80M	7.22M	7.97M	9.62M	9.37M	9.66M	9.87M	9.47M	12.58M	11.46M	10.67M	12.16M	12.16M	16.57M	16.64M
Deferred Taxes (Quarter)		142.48M	12.95M	-12.93M	13.30M	-25.70M	-14.68M	-3.87M	-11.51M	-9.70M	-9.42M	-1.29M	-14.24M	-0.29M	15.29M	2.86M	7.09M	-27.35M	16.77M	-3.43M
Gains from Investment Securities (Quarter)	0.50M	0.50M			0.22M	-0.30M	16.30M	0.41M	0.63M	0.17M	1.36M	1.24M	0.22M	-3.14M	4.76M	0.10M	0.64M	-0.73M	-2.62M	0.17M
Asset Writedowns and Impairment (Quarter)
Cash from Operations (Quarter)	36.89M	121.74M	82.52M	47.80M	40.23M	69.64M	82.45M	86.96M	66.84M	132.41M	102.35M	129.43M	55.79M	115.38M	178.47M	154.22M	99.71M	178.60M	219.03M	180.08M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)			-2.26M		11.40M	27.19M	-30.76M	1.83M	17.84M	20.34M	1.83M	17.76M	17.76M	17.76M	1.84M	17.76M	17.76M	17.76M	0.10M	2.25M
Amortization of Deferred Charges (Quarter)
Depreciation & Amortization (CF) (Quarter)	0.80M	0.70M	0.77M	0.78M	1.10M	2.00M	2.57M	2.62M	2.80M	2.70M	2.88M	2.40M	2.60M	2.60M	2.70M	2.70M	2.70M	2.70M	3.30M	4.20M
Change in Working Capital
Change in Receivables (Quarter)	64.81M	-41.10M	-21.12M	22.79M	9.46M	43.93M	7.75M	-36.19M	51.50M	-28.85M	16.89M	-38.31M	18.62M	71.22M	22.71M	-3.83M	11.72M	29.70M	90.48M	19.55M
Change in Inventory (Quarter)	0.09M	-2.73M	-2.22M	-6.30M	15.32M	5.51M	2.94M	7.25M	24.74M	-3.63M	-1.47M	40.23M	21.40M	-1.98M	7.73M	0.59M	14.54M	1.10M	-18.78M	-27.38M
Change in Accured Expenses (Quarter)	6.83M	-2.51M	3.47M	-6.01M	35.33M	-5.11M	0.33M	-24.01M	22.89M	-1.95M	-9.48M	18.68M	1.30M	-23.18M	50.19M	9.22M	-29.69M	-7.16M	33.85M	-24.92M
Other Working Capital Changes (Quarter)	-2.83M	-0.50M	0.99M	9.17M	-9.17M	-0.23M	9.29M	-8.88M	6.48M	-0.17M	-1.52M	-4.79M	43.54M	-38.48M	-5.62M	5.00M	36.07M	20.32M	-28.42M	9.11M
Investing Activities
Capital Expenditures (Quarter)	0.52M	0.50M	0.16M	0.49M	0.97M	1.01M	2.34M	11.38M	-10.72M	-0.12M	14.76M	1.51M	4.61M	1.52M	3.05M	0.49M	2.02M	3.03M	-4.64M	3.74M
Sales of Property, Plant and Equipment (Quarter)							9.98M
Acquisitions (Quarter)																				0.71M
Change in Acquisitions & Divestments (Quarter)	76.86M	24.97M	69.85M	136.00M	590.00M		20.13M	61.13M	53.37M	81.19M	15.60M	119.63M	53.96M	138.01M	83.98M	50.17M	189.11M	209.59M	273.38M	9.00M
Cash from Investing Activities (Quarter)	-44.62M	-16.95M	-299.47M	-49.30M	-434.95M	-1.01M	-1.75M	-60.16M	54.99M	-83.45M	-8.29M	-82.68M	-42.04M	-167.48M	29.48M	-90.42M	84.79M	201.61M	-741.79M	-2.88M
Financing Activities
Other financing activities (Quarter)	0.02M				6.00M		0.64M
Cash from Financing Activities (Quarter)	-44.76M	-60.07M	-156.01M	0.62M	367.82M	-12.40M	6.33M	-164.61M	2.45M	4.10M	-249.92M	-0.49M	9.48M	18.56M	-246.41M	-3.32M	-298.97M	-22.40M	239.51M	-1.61M
Additional items
Change in Cash (Quarter)	-52.48M	44.72M	-372.96M	-0.88M	-26.90M	56.23M	87.04M	-137.81M	124.28M	53.06M	-155.86M	46.26M	23.24M	-33.55M	-38.47M	60.48M	-114.47M	357.80M	-283.24M	175.59M
Free Cash Flow (Quarter)	36.37M	121.24M	82.36M	47.31M	39.26M	68.63M	80.11M	75.59M	77.56M	132.53M	87.59M	127.91M	51.18M	113.86M	175.41M	153.73M	97.69M	175.57M	223.67M	176.34M
Net Cash Flow (Quarter)	-52.48M	44.72M	-372.96M	-0.88M	-26.90M	56.23M	87.04M	-137.81M	124.28M	53.06M	-155.86M	46.26M	23.24M	-33.55M	-38.47M	60.48M	-114.47M	357.80M	-283.24M	175.59M

Research Tools

Developers

Halozyme Therapeutics Cash Flow Statement (2010-2026) | HALO

Research Tools

Developers

Halozyme Therapeutics Cash Flow Statement (2010-2026) | HALO

Create an account

Sign In

Reset Password